IVB103 / InnoVec Bio - LARVOL DELTA

Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD). (clinicaltrials.gov) - P1 | N=18 | Enrolling by invitation | Sponsor: InnoVec Biotherapeutics Inc. | Active, not recruiting ➔ Enrolling by invitation | Initiation date: Dec 2024 ➔ Apr 2025

Enrollment open • Trial initiation date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration